NASDAQ:DXR Daxor Q2 2026 Earnings Report $10.00 -0.30 (-2.91%) As of 08/21/2026 01:35 PM Eastern ProfileEarnings HistoryForecast Daxor EPS ResultsActual EPSN/AConsensus EPS -$0.03Beat/MissN/AOne Year Ago EPSN/ADaxor Revenue ResultsActual RevenueN/AExpected Revenue$2.80 millionBeat/MissN/AYoY Revenue GrowthN/ADaxor Announcement DetailsQuarterQ2 2026Date8/24/2026TimeAfter Market ClosesConference Call DateFriday, August 28, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Daxor Earnings HeadlinesDaxor (DXR) to Announce Quarterly Earnings on ThursdayAugust 19, 2026 | americanbankingnews.comDaxor (DXR) Stock Forecast & Price TargetAugust 11, 2026 | investing.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)Daxor Launches Blood Testing Lab in Eastern KansisJuly 31, 2026 | finance.yahoo.comDaxor Corporation Launches Outpatient Blood Volume Analysis Program at Kansas Healthcare FacilityJuly 29, 2026 | quiverquant.comQDaxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in KansasJuly 29, 2026 | globenewswire.comSee More Daxor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Daxor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daxor and other key companies, straight to your email. Email Address About DaxorDaxor (NASDAQ:DXR) is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload. In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting. The company offers training and technical support to hospital laboratories and specialty clinics, ensuring that staff are properly instructed in isotope handling, system operation and result interpretation. Through ongoing research collaborations, Daxor continuously evaluates new protocols and software enhancements to improve diagnostic performance and workflow efficiency. Headquartered in New York, Daxor serves healthcare providers in North America and has established distribution partnerships in Europe, Asia‐Pacific and select emerging markets. Its solutions are used by major university medical centers, community hospitals and research institutions to inform decisions on blood transfusion, fluid management and therapeutic intervention. The company’s management team brings decades of experience in medical technology commercialization, regulatory affairs and laboratory operations, positioning Daxor to expand its global footprint and address evolving needs in patient blood management.View Daxor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/17 - 08/21Flash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to WatchRoss Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss3 Stocks Came Roaring Back—Now They’re Flashing Warning SignsMicrosoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?Advance Auto Parts Plunged, But Its Turnaround Is Still Working Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
